

FISH & RICHARDSON P.C.

jc534 U.S. PTO

01/20/98

Frederick P. Fish
1855-1930

W.K. Richardson
1859-1951

A
225 Franklin Street
Boston, Massachusetts
02110-2804

Telephone
617 542-5070

Faximile
617 542-8906

January 20, 1998

Attorney Docket No.: 00216/414001

Box Patent Application

Assistant Commissioner for Patents
Washington, DC 20231

BOSTON

HOUSTON

NEW YORK

SOUTHERN CALIFORNIA

SILICON VALLEY

TWIN CITIES

WASHINGTON, DC

Presented for filing is a new original patent application of:

Applicant: PETER STYCZYNSKI AND GURPREET S. AHLUWALIA
Title: MODULATION OF HAIR GROWTH

Enclosed are the following papers, including those required to receive a filing date under 37 CFR §1.53(b):

	<u>Pages</u>
Specification	9
Claims	6
Abstract	1
Declaration	2
Drawing(s)	

Enclosures:

- Postcard.

Basic filing fee	790.00
Total claims in excess of 20 times \$22.00	902.00
Independent claims in excess of 3 times \$82.00	246.00
Fee for multiple dependent claims	270.00
Total filing fee:	\$ 2208.00

"EXPRESS MAIL" Mailing Label Number EM 040 826 341 US

Date of Deposit January 20, 1998

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Justin M. Goren
Justin M. Goren

FISH & RICHARDSON P.C.

January 20, 1998

Page 2

A check for the filing fee is enclosed. Please apply any other required fees or any credits to deposit account 06-1050, referencing the attorney docket number shown above.

If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at 617/542-5070.

Kindly acknowledge receipt of this application by returning the enclosed postcard.

Please send all correspondence to:

Robert C. Nabinger
Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804

Respectfully submitted,


Robert C. Nabinger
Reg. No. 33,431
Enclosures
284491.B11

CONFIDENTIAL
DO NOT COPY

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: **MODULATION OF HAIR GROWTH**

APPLICANT: **PETER STYCZYNSKI AND GURPREET S. AHLUWALIA**

"EXPRESS MAIL" Mailing Label Number EM 040 826 341 US

Date of Deposit January 20, 1998

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Justin McGovern

Justin McGovern

MODULATION OF HAIR GROWTH

Background of the Invention

5 The invention relates to modulating hair growth in mammals.

10 A main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic 10 reasons. For example, it is generally preferred to have hair on the scalp but not on the face.

15 Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic antiandrogens. These conventional procedures generally have drawbacks associated with them. Shaving, for instance, can cause nicks and cuts, and can leave a perception of an increase in the rate of hair regrowth. Shaving also can 20 leave an undesirable stubble. Electrolysis, on the other hand, can keep a treated area free of hair for prolonged periods of time, but can be expensive, painful, and sometimes leaves scarring. Depilatory creams, though very effective, typically are not recommended for frequent use 25 due to their high irritancy potential. Waxing and plucking can cause pain, discomfort, and poor removal of short hair. Finally, antiandrogens -- which have been used to treat female hirsutism -- can have unwanted side effects.

30 It has previously been disclosed that the rate and character of hair growth can be altered by applying to the skin inhibitors of certain enzymes. These inhibitors include inhibitors of 5-alpha reductase, ornithine decarboxylase, S-adenosylmethionine decarboxylase, gamma-glutamyl transpeptidase, and transglutaminase. See, for 35 example, Breuer et al., U.S. Pat. No. 4,885,289; Shander,

U.S. Pat. No. 4,720,489; Ahluwalia, U.S. Pat. No. 5,095,007; Ahluwalia et al., U.S. Pat. No. 5,096,911; Shander et al., U.S. Pat. No. 5,132,293; and Shander et al., U.S. Pat. No. 5,143,925.

5 The growth of hair results from many complex and interactive processes. In one process sex steroid androgens, particularly testosterone, act on, for example, beard hair follicles on the face to stimulate hair growth. But these same androgens can inhibit hair growth on the
10 scalp, particularly in those that have a genetic predisposition for male-pattern baldness or androgenetic alopecia.

15 Cytochrome P450s, epoxide hydrolases, glutathione-S-transferases, UDP-glucuronosyltransferases (UGTs), and sulfotransferases (STs) are families of enzymes that are involved in the metabolism of xenobiotics and other substances that are endogenous to the human body. Generally, the enzymes catalyze the conversion of a substrate (e.g., a particular steroid) to a form that is
20 more readily eliminated from the body. For example, glutathione-S-transferases catalyze the conjugation of the substrate with glutathione; UGTs catalyze the conjugation of substrate with glucuronic acid; and STs catalyze the conjugation of the substrate with a sulfonate moiety. It is
25 believed that these substrate conjugates are more water soluble than the substrate itself, and thus more readily eliminated from the body. Some of these enzymes can be induced by compounds, such as 3-methylcholanthrene and phenobarbital.

30 Steroids are substrates for several isoforms of UGT, with overlapping specificities. For example, rat liver UGTr-3 catalyzes the glucuronidation of dihydrotestosterone, testosterone and β -estradiol, whereas in addition to these

steroids UGTr-2 also catalyzes 4-hydroxybiphenyl, chloramphenicol and 4-methylumbelliferone glucuronoconjugation (Chen et al., Biochem. 32: 10648-10657).

5

Summary of the Invention

In one aspect, the invention features modulating hair growth by topical application of a compound that induces or activates the conjugation of an androgen (e.g., testosterone) that is involved in hair growth. By "induces" 10 or "activates", we mean that the compound increases the conjugating enzyme levels in the hair follicle cells and/or increases the catalytic activity of the conjugating enzyme for conjugation. The compound may, for example, induce or activate a UGT or an ST for which the androgen serves as the 15 substrate.

The modulation in hair growth depends on whether the hair growth selected for treatment is androgen-stimulated hair growth (e.g., beard hair and torso hair generally in humans) or hair growth that is not androgen-stimulated 20 (e.g., scalp hair in humans). Topical application of the compound in a dermatologically acceptable vehicle to an area of skin having androgen-stimulated hair growth generally causes a reduction in hair growth. Topical application of the compound in a dermatologically acceptable vehicle to an 25 area of skin having hair growth (i.e., from the scalp) that is reduced in the presence of androgens, (e.g., because of androgenic alopecia) generally causes an increase in hair growth.

In another aspect, the invention features modulating 30 hair growth by topical application of a compound that induces or activates a UGT.

In another aspect, the invention features modulating hair growth by topical application of a compound that induces or activates an ST.

In another aspect, the invention features modulating hair growth by topical application of a compound that induces or activates the conversion of an androgen involved in hair growth to a less active (e.g., more water soluble) metabolite.


Other features and advantages of the invention will be apparent from the Description of Preferred Embodiments thereof, and from the claims.

Description of Preferred Embodiments

Compounds that activate or induce UGTs are known. Such compounds include ethoxyquin, 5,7-dihydroxy-4'-methoxyflavone, butylhydroxyanisole, phenobarbital, naringenin, butylhydroxytoluene, flavone, tioconazole, trans-1,2-bis(2-pyridyl)ethylene, 7,4'-isoflavandiol, (equol), galangin, 7-hydroxy-4'-methoxyisoflavone (formononetin), 5,4'-dihydroxy-7-methoxyisoflavone (prunetin), and daidzein. These compounds induce UGTs relevant to testosterone glucononidation.

Examples of androgens that may be conjugated include testosterone, dihydrotestosterone, androstenedione, androstanediols, and dehydroepiandrosterone.

It is believed that the compounds act according to the pathway shown below (in which testosterone is used as an example):



The compound may induce or activate, for example, UGTs that catalyze the conjugation of testosterone with glucuronic acid (donated from uridine diphosphoglucuronic acid) or STs that catalyze the conjugation of testosterone with a sulfonate group (donated from 3'-phosphoadenosine 5'-phosphosulfate).

The compound preferably is incorporated in a topical composition that includes a non-toxic dermatologically acceptable vehicle or carrier which is adapted to be spread upon the skin. Examples of suitable vehicles are acetone, alcohols, or a cream, lotion, or gel which can effectively deliver the active compound. A vehicle is disclosed in U.S. Patent No. 5,648,394. In addition, a penetration enhancer may be added to the vehicle to further enhance the effectiveness of the formulation.

The concentration of the compound in the composition may be varied over a wide range up to a saturated solution, preferably from 0.1% to 30% by weight or even more; the reduction or increase in hair growth rises as the amount of inhibitor applied increases per unit area of skin. The maximum amount effectively applied is limited only by the rate at which the compound penetrates the skin. The effective amounts may range, for example, from 10 to 3000 micrograms or more per square centimeter of skin.

A composition may include more than one of the compounds.

The composition should be topically applied to a selected area of the body from which it is desired to reduce hair growth (if the hair growth is androgen-stimulated hair growth) or increase hair growth (if the hair loss is androgen dependent). For example, in humans the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek, neck, upper lip, and chin to

obtain a reduction in hair growth. The composition can also be applied to the legs, arms, torso or armpits to obtain a reduction in hair growth. The composition can be applied to the scalp to obtain an increase in hair growth. The 5 composition is particularly suitable for reducing the growth of unwanted hair in women suffering from hirsutism or other similar conditions.

In humans, the composition, for example, may be applied once or twice a day, or even more frequently, for 10 two weeks to six months (e.g., three months) to achieve a perceived effect. Reduction in hair growth is demonstrated when the frequency of hair removal is reduced or the subject perceives less hair on the treated site, or quantitatively, when the weight of hair removed by shaving (i.e., hair mass) 15 is reduced. Increase in hair growth is demonstrated when the opposite effect is observed.

Male intact Golden Syrian hamsters are considered acceptable models for human beard hair growth and other androgen-stimulated hair growth in that they display oval 20 shaped flank organs, one on each side, each about 8 mm. in major diameter, which grow thick black and coarse hair similar to human beard hair. These organs produce hair in response to androgens in the hamster. To evaluate the effectiveness of a composition in reducing androgen- 25 stimulated hair growth, the flank organs of each of a group of hamsters are shaved. To one organ of each animal 10 μ l. of composition vehicle alone once a day is applied, while to the other organ of each animal an equal amount of the composition (including the relevant compound or compounds). 30 After thirteen applications (one application per day for five days a week), the flank organs are shaved and the amount of recovered hair (hair mass) from each is weighed. Percent-reduction of hair growth is calculated by

subtracting the hair mass (mg) value of the test compound treated side from the hair mass value of the vehicle treated side; the delta value obtained is then divided by the hair mass value of the vehicle treated side, and the resultant number is multiplied by 100.

The above-described assay will be referred to herein as the "Golden Syrian hamster" assay. Preferred compositions provide a reduction in hair growth of at least about 30%, more preferably at least about 50%, and most preferably at least about 60% when tested in the Golden Syrian hamster assay.

A number of compositions containing compounds that induce or activate UGTs for which testosterone is a substrate were tested in the Golden Syrian hamster assay; the results are provided in Table I:

TABLE I

	<u>Compound</u>	<u>Vehicle</u>	<u>Left (mg)</u>	<u>Right (mg)</u>	<u>% Inhibition</u>
	ethoxyquin	A	0.55 ± .16	2.41 ± .11	75 ± 7
	5,7-dihydroxy-4'-methoxyflavone	B	1.00 ± .22	2.61 ± .27	62 ± 9
20	butylhydroxyanisole	A	0.92 ± .24	2.27 ± .11	61 ± 9
	phenobarbital	A	0.89 ± .16	1.88 ± .24	51 ± 11
	naringenin	A	1.42 ± .18	2.46 ± .20	40 ± 8
	butylhydroxytoluene	C	1.74 ± .38	2.05 ± .36	22 ± 18
25	flavanone	C	1.91 ± .22	2.39 ± .22	17 ± 10

All compounds were administered as a 10% doses. Vehicle A = ethanol 80%, H₂O 17.5%, propylene glycol dipelargonate 2%, propylene glycol 0.5%; B = ethanol 70%, dimethylsulfoxamine 30%; C = propylene glycol 50%, ethanol 25%, dimethylsulfoxide 25%.

An assay was performed to evaluate whether some of the compounds tested in the Golden Syrian Hamster assay caused an induction of testosterone glucuronide formation.

Flank organ homogenates were prepared by adding 4 flank organs into 2 mL of a buffer containing 25 mM Tris/50 mM sucrose, pH 7.4 and homogenized with a Polytron (Brinkman Instruments) while keeping the mixture on ice. The

glucuronidation of testosterone was measured by incubating the 20 μ l of the flank organ protein (1 mg/ml) with [14 C]-testosterone 125 μ M and UDP-glucuronic acid (5mM) in the presence of buffer containing 0.5M Tris, pH 7.5 and 0.1 M $MgCl_2$. The total reaction mixture volume was 100 μ l. Assay mixtures were incubated at 37°C for 60 minutes, and reactions were stopped with the addition of 3.5 ml methylene chloride. An aqueous carrier (250 μ l water) was added to each reaction mixture which was then shaken and centrifuged. The unmetabolized [14 C]-testosterone remained in the organic phase whereas the testosterone glucuronide partitioned into the aqueous phase, and was quantitated by scintillation spectrometry. The results are provided in Table II:

TABLE II

15	<u>Compound</u>	<u>% Induction</u>
	ethoxyquin	214
	butylhydroxyanisole	178
	5,7-dihydroxy-4'-methoxyflavone	120
	phenobarbital	113

20 It was believed that the diversion of testosterone away from its biologically active species to a glucuronide or sulfonate conjugate would have effects on the flank organs of the Golden Syrian hamster since testosterone is known to regulate the existence of these unique organs. The 25 diameter of flank organs were assessed using a caliper following topical treatment of the hamsters with ethoxyquin or 5,7-dihydroxy-4'-methoxyflavone as described in the hair mass assay section. A decrease in flank organ diameter was demonstrated following topical application of the compounds 30 (Table III). These data are consistent with the hypothesis that suggests that local induction of conjugating enzymes, such as UGTs, can diminish the biological activity of testosterone.

TABLE III

<u>Treatment</u>	<u>Treated FO (mm)</u>	<u>Vehicle FO (mm)</u>	<u>Decrease (mm)</u>	<u>% Decrease</u>
ethoxyquin	7.18 ± .26	8.83 ± .28	1.65 ± .37	19 ± 4
5,7-dihydroxy-4'-methoxyflavone	8.04 ± .29	9.08 ± .43	1.04 ± .46	12 ± 5

5 Other embodiments are within the claims.

Claims

1 1. A method of reducing mammalian androgen-
2 stimulated hair growth, which comprises
3 selecting an area of skin from which hair grows in
4 response to androgen-stimulation from which reduced hair
5 growth is desired; and
6 applying to said area of skin a dermatologically
7 acceptable composition comprising a compound that induces or
8 activates a UDP-glucuronosyltransferase or a
9 sulfotransferase, wherein the compound is present in the
10 composition in an amount effective to reduce hair growth.

1 2. A method of increasing mammalian hair growth,
2 which comprises
3 selecting an area of skin from which hair grows that
4 does not grow in response to androgens from which increased
5 hair growth is desired; and
6 applying to said area of skin a dermatologically
7 accepted composition comprising a compound that induces or
8 activates a UDP-glucuronosyltransferase or a
9 sulfotransferase, wherein the compound is present in the
10 composition in an amount effective to increase hair growth.

1 3. The method of claim 1 or 2, wherein said
2 compound comprises ethoxyquin.

1 4. The method of claim 1 or 2, wherein said
2 compound comprises 5,7-dihydroxy-4'-methoxyflavone.

1 5. The method of claim 1 or 2, wherein said
2 compound comprises butylhydroxyanisole.

1 6. The method of claim 1 or 2, wherein said
2 compound comprises phenobarbital.

1 7. The method of claim 1 or 2, wherein said
2 compound comprises naringenin.

1 8. The method of claim 1 or 2, wherein said
2 compound comprises butylhydroxytoluene.

1 9. The method of claim 1 or 2, wherein said
2 compound comprises flavone.

1 10. The method of claim 1 or 2, wherein said
2 compound comprises tioconazole.

1 11. The method of claim 1, wherein said compound
2 comprises trans-1,2-bis(2-pyridyl)ethylene.

1 12. The method of claim 1 or 2, wherein said
2 compound comprises 7,4'-isoflavandiol.

1 13. The method of claim 1 or 2, wherein said
2 compound comprises galangin.

1 14. The method of claim 1 or 2, wherein said
2 compound comprises 7-hydroxy-4'-methoxyisoflavone.

1 15. The method of claim 1 or 2, wherein said
2 compound comprises 5,4'-dihydroxy-7-methoxyisoflavone.

1 16. The method of claim 1 or 2, wherein said
2 compound comprises daidzein.

1 17. The method of claim 1, wherein said compound
2 induces or activates a UDP-glucuronosyltransferases.

1 18. The method of claim 2, wherein said compound
2 induces or activates a sulfotransferase.

1 19. The method of claim 1 or 2, wherein said
2 androgen comprises testosterone.

1 20. The method of claim 1 or 2, wherein the
2 concentration of said compound in said composition is
3 between 0.1% and 30%.

1 21. The method of claim 1 or 2, wherein the
2 composition provides a reduction in hair growth of at least
3 15% when tested in the Golden Syrian hamster assay.

1 22. The method of claim 1 or 2, wherein the
2 composition provides a reduction in hair growth of at least
3 40% when tested in the Golden Syrian hamster assay.

1 23. The method of claim 1 or 2, wherein said mammal
2 is a human.

1 24. The method of claim 1, wherein the area of skin
2 is on the face of the human.

1 25. The method of claim 24, wherein said human is a
2 woman suffering from hirsutism.

1 26. The method of claim 2, wherein the area of skin
2 is on the scalp of a human.

1 27. A method of reducing mammalian androgen-
2 stimulated hair growth, which comprises
3 selecting an area of skin from which hair grows in
4 response to androgen-stimulation from which reduced hair
5 growth is desired; and
6 applying to said area of skin a dermatologically
7 acceptable composition comprising a compound that induces or
8 activates the conjugation of an androgen that stimulates
9 androgen-stimulated hair growth to produce a conjugate of
10 the androgen, wherein the compound is present in the
11 composition in an amount effective to reduce the hair
12 growth.

1 28. The method of claim 27, wherein the area of
2 skin is on the face of a human.

1 29. A method of increasing mammalian hair growth,
2 which comprises
3 selecting an area of skin from which hair does not
4 grow in response to androgens from which increased hair
5 growth is desired; and
6 applying to said area of skin, a dermatologically
7 acceptable composition comprising a compound that induces or
8 activates the conjugation of an androgen that retards hair
9 growth to produce a conjugate of the androgen, wherein the
10 compound is present in the composition in an amount
11 effective to increase the hair growth.

1 30. The method of claim 29, wherein the area of
2 skin includes the scalp of a human.

1 31. The method of claim 27 or 29, wherein the
2 compound is an inducer or activator of an androgen
3 conjugation enzyme.

1 32. The method of claim 31, wherein the androgen
2 comprises a testosterone.

1 33. The method of claim 31, wherein the androgen
2 comprises dihydrotestosterone.

1 34. The method of claim 31, wherein the androgen
2 comprises an androgen selected from the group consisting of
3 androstanedione, androstanediols, and
4 dehydroepiandrosterone.

1 35. A method of reducing mammalian androgen-
2 stimulated hair growth, which comprises
3 selecting an area of skin from which hair grows in
4 response to androgen-stimulation from which reduced hair
5 growth is desired; and
6 applying to said area of skin a dermatologically
7 acceptable composition comprising a compound that induces or
8 activates the conversion of testosterone to a less active
9 metabolite, wherein the compound is present in the
10 composition in an amount effective to reduce the hair growth
11 from the area of skin.

1 36. The method of claim 35, wherein the area of
2 skin is on the face of a human.

1 37. The method of claim 35, wherein the less active
2 metabolite comprises a compound that is more water soluble
3 than testosterone.

1 38. A method of increasing hair growth from the
2 scalp of a human, which comprises
3 selecting an area of the scalp of a human from which
4 increase hair growth is desired; and
5 applying to the area of the scalp a dermatologically
6 acceptable composition comprising a compound that induces or
7 activates the conversion of testosterone to a less active
8 metabolite, wherein the compound is present in the
9 composition in an amount effective to increase hair growth
10 from the area of the scalp.

1 39. The method of claim 38, wherein the less active
2 metabolite comprises a compound that is more water soluble
3 than testosterone.

MODULATION OF HAIR GROWTH
Abstract of the Disclosure

Mammalian hair growth may be modulated by applying to the skin a compound that induces or activates the conjugation of an androgen.

280641.B11

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled MODULATION OF HAIR GROWTH, the specification of which

is attached hereto.

was filed on _____ as Application Serial No. _____
and was amended on _____.

was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Robert C. Nabinger, Reg. No. 33,431; Sean P. Daley, Reg. No. 40,978; Donal B. Tobin, Reg. No. 25,711; Paul I. Douglas, Reg. No. 31,244; Chester Cekala, Reg. No. 32,971; Stephan P. Williams, Reg. No. 28,546; Edward S. Podszus, Reg. No. 35,983; David A. Howley, Reg. No. 34,624; Thomas G. Krivulka, Reg. No. 38,525; Charles P. Boukus, Jr., Reg. No. 24,754; and Joseph N. Handleman, Reg. No. 26,179.

Address all telephone calls to Robert C. Nabinger at telephone number 617/542-5070.

Address all correspondence to Robert C. Nabinger, Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: Peter Styczynski

Inventor's Signature: Peter Styczynski Date: January 16, 1988

Residence Address: 3709 Roop Road, New Windsor, MD 21776

Citizen of: U.S.A.

Post Office Address: P.O. Box 387, Mt. Airy, MD 21771

COMBINED DECLARATION AND POWER OF ATTORNEY CONTINUED

Full Name of Inventor: Gurpreet S. Ahluwalia

Inventor's Signature: Gurpreet S. Ahluwalia Date: January 16, 1998


Residence Address: 8632 Stableview Court, Gaithersburg, MD 20882

Citizen of: U.S.A.

Post Office Address: 8632 Stableview Court, Gaithersburg, MD 20882

283786 B11

United States Patent & Trademark Office
Office of Initial Patent Examination – Scanning Division



Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
 - All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
Pages _____ do not meet these requirements.
 - Papers are not flexible, strong, smooth, non-shiny, durable, and white.
 - Papers are not typewritten or mechanically printed in permanent ink on one side.
 - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
 - Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
 - The drawings or copy of drawings are not suitable for electronic reproduction.
 - All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
 - Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) _____ are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) _____ are missing.
5. OTHER: No Drawings